Verastem

VSTM NASDAQ
1.390
+0.100
+7.75%
Closed 16:00 08/21 EDT
Open
1.290
Prev Close
1.290
High
1.430
Low
1.290
Volume
1.13M
Avg Vol (3M)
1.75M
52 Week High
10.35
52 Week Low
1.160
% Turnover
1.52%
Market Cap
103.06M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Verastem VSTM stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.
MORE >

Recently

Name
Price
%Change